当前位置:首页>关于我们
公司介绍

  血霁生物是由海归专家创立的干细胞生物医药公司,致力于通过干细胞定向再生血液细胞,以用于各类疾病的细胞治疗以及开展相关药物研发。 公司创始成员来自斯坦福大学、哈佛大学、北京大学等国内外著名高校。基于全球领先的干细胞定向诱导分化体系,血霁生物以体 外产生的血小板为先导产品,解决癌症、肝病、急危重症、血液疾病等疾病中急缺的血小板需求,以及开发各类血小板异常相关疾病的创新药物。

HemaCell Therapeutics is a stem cell-based biotech company founded by expert of stem cell biology and regenerative medicine and the founding members graduated from Stanford University, Harvard University and Peking University. The company is dedicated to developing various blood products from stem cells for cell therapy and our primary focus is platelets. Stem cell-derived platelets can serve as new unlimited supply for transfusion medicine to treat thrombocytopenia caused by a wide spectrum of diseases, including cancer, liver disease, acute and critical illness and blood diseases. With its proprietary highly efficient ex-vivo directed differentiation system, the company provides the most promising solution to the critically unmet needs of platelet supply in the clinic.

创始团队